Abraxane Articles
Elan and Celgene settle over Abraxane; Watson re-challenges Shire Adderall XR patent
28 February 2011
Breast cancer drug Abraxane now available in New Zealand
22 February 2011
Increased uptake of FOLFIRINOX and launch of Abraxane will see dynamic change in treatment of pancreatic cancer patients
23 November 2010
Celgene to buy Abraxis in $2.9 billion cash and stock deal, bagging the latter’s cancer drug Abraxane
1 July 2010
Abraxane rights cost deepens Abraxis' loss
16 March 2009
Abraxane launched in Germany
9 February 2009
18% of BC patients see complete response with Abraxane regimen
22 December 2008
Abraxis launches Abraxane in EU
22 December 2008
Abraxis seeks to reacquire US Abraxane marketing rights from AZ
1 December 2008
Abraxane gains marketing OK in Australia
27 October 2008
NCCN to test Abraxane for SPARC benefits
13 October 2008
Biocon/Abraxis debut Abraxane in India
28 July 2008
Abraxis to appeal ruling on Elan patent
23 June 2008
Abraxis reports Phase I results for Abraxane
28 April 2008
Taiho submits Japanese NDA for Abraxis BioSci's Abraxane
24 March 2008
Abraxis licenses Abraxane to Green Cross for Korea
3 December 2007
Abraxane gets CHMP nod for breast cancer
29 October 2007
Abraxis out-licenses Abraxane for India
13 August 2007
Genta's Genasense shows preclinical efficacy
20 November 2006
Abraxis to buy Puerto Rico unit from Pfizer
1 May 2006
APP and American Biosci complete merger to form Abraxis
24 April 2006
American Pharma to buy shareholder
5 December 2005
Abraxane Ph II trial finishes recruitment
16 May 2005
APP reports start of Ph II trial of Abraxane/Herceptin
18 April 2005
Strong results for APP's Abraxane
7 March 2005
American PP announces Abraxane launch date
7 February 2005
Abraxane cleared for breast cancer by FDA
17 January 2005
Abraxane filed for US approval
15 March 2004
Showing 1-42 of 42 articles
- 1
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
